Caribou Biosciences (CRBU) Change in Receivables (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Change in Receivables of $158000.0 for Q1 2026, up 189.27% year-over-year from $54621.1 in Q1 2025, and up 191.33% quarter-over-quarter from -$173000.0 in Q4 2025.
Caribou Biosciences (CRBU) Change in Receivables (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Change in Receivables for 7 consecutive years, with $158000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables rose 189.27% year-over-year to $158000.0; the TTM figure through Mar 2026 stood at $139000.0 (up 116.75% YoY), while the FY2025 annual figure was -$196000.0, down 267.52% from the prior year.
- Change in Receivables grew to $158000.0 in Q1 2026 per CRBU's latest filing, from -$173000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $1.3 million in Q1 2023 and bottomed at -$985000.0 in Q4 2023.
- Historically, Change in Receivables has averaged -$54470.6 across 5 years, with a median of -$32000.0 in 2024.
- Annual changes were most pronounced in 2022 — Change in Receivables sank 952.7% — and 2025, when it jumped 634.38%.
- Caribou Biosciences' Change in Receivables stood at -$195000.0 in 2022, then slumped by 405.13% to -$985000.0 in 2023, then jumped by 108.22% to $81000.0 in 2024, then plunged by 313.58% to -$173000.0 in 2025, then jumped by 191.33% to $158000.0 in 2026.
- Business Quant data shows CRBU's Change in Receivables at $158000.0 in Q1 2026, -$173000.0 in Q4 2025, and $171000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | -24,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24,000.00 |
| Jun 30, 2026 | -24,000.00 |
| Mar 31, 2026 | 158,000.00 |
| Mar 31, 2026 | 158,000.00 |
| Dec 31, 2025 | -173,000.00 |
| Dec 31, 2025 | -173,000.00 |
| Sep 30, 2025 | 171,000.00 |
| Sep 30, 2025 | 171,000.00 |
| Jun 30, 2025 | -17,000.00 |
| Jun 30, 2025 | -17,000.00 |
| Mar 31, 2025 | -177,000.00 |
| Mar 31, 2025 | -177,000.00 |
| Dec 31, 2024 | 81,000.00 |
| Dec 31, 2024 | 81,000.00 |
| Sep 30, 2024 | -32,000.00 |
| Sep 30, 2024 | -32,000.00 |
| Jun 30, 2024 | -702,000.00 |
| Jun 30, 2024 | -702,000.00 |
| Mar 31, 2024 | 770,000.00 |
| Mar 31, 2024 | 770,000.00 |